Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU. (Q38066412)

28 August 2017

1 reference

title

Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU. (English)

1 reference

Katherine A Lyseng-Williamson

28 August 2017

0 references

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

28 August 2017

2

Kate McKeage

1 reference

28 August 2017

publication date

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

30

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

51-58

1 reference

Dementia and Alzheimer disease incidence: a prospective cohort study.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Combination therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Pharmacodynamics of memantine: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine benefits functional abilities in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine (Ebixa) in clinical practice - results of an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Cost effectiveness of memantine in Alzheimer's disease in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine: a review of its use in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-012-0041-0

Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.

21 January 2018

1 reference

12 December 2020

Effective pharmacological management of Alzheimer's disease.

1 reference

12 December 2020

The costs of Alzheimer's disease and the value of effective therapies

1 reference

12 December 2020

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands

1 reference

12 December 2020

10.1007/S40266-012-0041-0

Identifiers

DOI

1 reference

28 August 2017

1 reference